InternationalScored off the official board: an annual-only filer, so this data lags a domestic quarterly filer.

13F Pro Quality Score

32.0/100

Rank #2,439 of 2,960 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

PRGO Stock Analysis & AI Quality Score

Data updated 2026-09-12

AI stock analysis and institutional research for PERRIGO Co plc (PRGO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PRGO at 32.0/100 on a 32-signal composite quality model, placing it at rank #2,439 of 2,960 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), PERRIGO Co plc reports quarterly revenue of $1.0B, net income of $74.5M, free cash flow of $68.3M. Top institutional holders of PRGO by reported 13-F value include BlackRock, Neuberger Berman Group, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. PRGO trades on the NYSE exchange and files with the SEC under CIK 1585364. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PRGO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PERRIGO Co plc directly from SEC EDGAR. PERRIGO Co plc's 13F Pro composite quality score has ranged between 32 and 47 since 2026, currently 32.0 — a declining long-term trajectory across 49 quarterly and live scoring snapshots.

Fun facts about PERRIGO Co plc

Quirks, history, and lore behind PRGO — the kind of stuff that makes a stock memorable.

  • 1
    The Basics
    A healthcare company incorporated in Ireland but operationally rooted in the U.S. Midwest · listed on Nasdaq · focused on making medicine more affordable.
  • 2
    The Numbers
    Annual revenue in the range of $4–5 billion, with operations spanning over 30 countries — not a giant, but quietly one of the largest OTC drugmakers on earth.
  • 3
    The History
    Founded in 1887 in Michigan, it spent most of its life as a quiet Midwestern manufacturer before exploding into a global powerhouse through aggressive acquisitions in the 2000s and 2010s.
  • 4
    The Secret
    Its entire business model is essentially 'name-brand medicine, minus the name' — it manufactures the store-brand versions of your favorite over-the-counter drugs for retailers worldwide.
  • 5
    The Lore
    It redomiciled to Ireland via inversion after acquiring a European rival, drawing scrutiny from U.S. lawmakers at a time when tax inversions were Washington's favorite villain.
  • 6
    The Giveaway
    When you grab the store-brand ibuprofen or sleep aid off the shelf at Walmart, CVS, or Walgreens, there's a very good chance the pill inside came from this Allegan, Michigan–rooted OTC giant.
▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$1.0B

Net Income

Q2 2026

$74.5M

Free Cash Flow

Q2 2026

$68.3M

ROIC

Q2 2026

1.6%

D/E Ratio

Q2 2026

1.31

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-2.8% YoY
$4.25BFY 2025
FY22 $4.45BFY23 $4.66BFY24 $4.37BFY25 $4.25B

Net Income

-729.7% YoY
$-1.43BFY 2025
FY22 $-140.6MFY23 $-12.7MFY24 $-171.8MFY25 $-1.43B

Operating Income

-1094.0% YoY
$-1.12BFY 2025
FY22 $78.9MFY23 $151.9MFY24 $112.9MFY25 $-1.12B

EPS (Diluted)

-723.2% YoY
$-10.29FY 2025
FY22 $-1.04FY23 $-0.09FY24 $-1.25FY25 $-10.29

Total Assets

-11.5% YoY
$8.54BFY 2025
FY22 $11.02BFY23 $10.81BFY24 $9.65BFY25 $8.54B

Total Debt

+0.6% YoY
$3.64BFY 2025
FY22 $4.11BFY23 $4.07BFY24 $3.62BFY25 $3.64B

Op. Cash Flow

-34.3% YoY
$238.5MFY 2025
FY22 $307.3MFY23 $405.5MFY24 $362.9MFY25 $238.5M

Free Cash Flow

-40.7% YoY
$145.1MFY 2025
FY22 $210.9MFY23 $303.8MFY24 $244.6MFY25 $145.1M

Get alerted when PRGO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for PERRIGO Co plc including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Top Institutional Holders of PRGO

Companies Similar to PRGO

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

XRAY

DENTSPLY SIRONA Inc.

38
AI score
Similar quality profile · 21 shared holders
QDEL

QuidelOrtho Corp

29
AI score
Similar quality profile · 13 shared holders
CRL

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

43
AI score
Similar quality profile · 6 shared holders
HUN

Huntsman CORP

38
AI score
Similar quality profile · 13 shared holders
ENOV

Enovis CORP

37
AI score
Similar quality profile · 10 shared holders
SRPT

Sarepta Therapeutics, Inc.

32
AI score
Similar quality profile · 11 shared holders
TDOC

Teladoc Health, Inc.

40
AI score
Similar quality profile · 11 shared holders
AHCO

AdaptHealth Corp.

43
AI score
Similar quality profile · 7 shared holders

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

Put PRGO on your watchlist

Track score changes the day PERRIGO Co plc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is PRGO a good stock to buy?

13F Pro's AI-powered analysis of PERRIGO Co plc (PRGO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PRGO are available on the PRGO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. PRGO is classified as a small company.

Which hedge funds own PRGO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PRGO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of PERRIGO Co plc's investment landscape.